CAJ | 학술논문

目的观察吉西他滨瘤内给药治疗大鼠脑胶质瘤的效果,探讨治疗脑胶质瘤的有效化疗途径及药物.方法 50只SD大鼠随机分为对照组(5只),肿瘤组和治疗(1 mg/ml)组和治疗(4mg/ml)组,每组15只.除对照组外,所有大鼠均在纹状体部埋植导管,并接种9L胶质瘤细胞株以建立在体脑胶质瘤模型.治疗组于植入瘤细胞第9天,通过导管将吉西他滨(10μl,1 mg/ml和4 mg/ ml)分别注入瘤内.于给药第9天,每组随机取脑抽检(5只),观察瘤形态及大小;余者(每组10只)观察其饮食、行为、体质量及存活期,评价吉西他滨对大鼠脑胶质瘤的治疗效果.结果于瘤内注入吉西他滨第9天取脑,发现各组肿瘤大小分别为:肿瘤组(44.69±7.52) mm3、治疗(1 mg/ml)组(22.44±5.37) mm3和治疗(4 mg/ml)组(18.72±7.13)mm3,肿瘤组与两治疗组间差异有统计学意义(P＜0.05),但两治疗组之间差异无统计学意义(P＞0.05).治疗组大鼠体质量下降较肿瘤组为轻.肿瘤组平均存活期为23.8d.4 mg/ml组1只存活期比肿瘤组短,剩余4只及全部1 mg/ml组(10只)均长于肿瘤组.结论吉西他滨可抑制脑胶质瘤生长,缓解大鼠体质量下降,延长模型动物存活期,对大鼠脑胶质瘤具有抑制作用.
목적 관찰길서타빈류내급약치료대서뇌효질류적효과,탐토치료뇌효질류적유효화료도경급약물.방법 50지SD대서수궤분위대조조(5지),종류조화치료(1 mg/ml)조화치료(4mg/ml)조,매조15지.제대조조외,소유대서균재문상체부매식도관,병접충9L효질류세포주이건립재체뇌효질류모형.치료조우식입류세포제9천,통과도관장길서타빈(10μl,1 mg/ml화4 mg/ ml)분별주입류내.우급약제9천,매조수궤취뇌추검(5지),관찰류형태급대소;여자(매조10지)관찰기음식、행위、체질량급존활기,평개길서타빈대대서뇌효질류적치료효과.결과 우류내주입길서타빈제9천취뇌,발현각조종류대소분별위:종류조(44.69±7.52) mm3、치료(1 mg/ml)조(22.44±5.37) mm3화치료(4 mg/ml)조(18.72±7.13)mm3,종류조여량치료조간차이유통계학의의(P＜0.05),단량치료조지간차이무통계학의의(P＞0.05).치료조대서체질량하강교종류조위경.종류조평균존활기위23.8d.4 mg/ml조1지존활기비종류조단,잉여4지급전부1 mg/ml조(10지)균장우종류조.결론 길서타빈가억제뇌효질류생장,완해대서체질량하강,연장모형동물존활기,대대서뇌효질류구유억제작용.
Objective To determine the possible efficacy of gecitabine against malignant glioma in the model rat to give some clues for clinical treatment.Methods Malignant glioma models were set up by implanting 9 L cells in striatum in rats.50 model rats were divided randomly into control group (5 rats),tumor group,1 mg/ml group and 4 mg/ml group with 15 rats in each.Gecitabine (10 μl,1 mg/ml or 4 mg/ml) was delivered into the tumor by catheter at 9th day after the implanting of 9 L cells.5 rats from each group were collected randomly to detect the size of tumor in brain at 9th day after the administration of gecitabine.For the rest rats,the status abous eating,drinking,weight and life span (after 9 L cells were implanted) were recorded respectively.Results The size of tumors under gecitabine administration was smaller than that of the tumor group [tumor group (44.69±7.52) mm3,1 mg/ml group (22.44±5.37) mm3,4 mg/ml group (18.72±7.13) mm3],there were satestically significances between tumor group and gecitabine groups (P ＜ 0.05),but there was not between the two gecitatine groups (P ＞ 0.05).The losses of weight in gecitabine groups were minored compared with tumor group.The mean survival of the rats in tumor group was 23.8 d.Except for 1 rat in 4 mg/ml gecitabine group,the survivals of the other rats in 4 mg/ml group and all rats in 1 mg/ml group were longer than that in tumor group.Conclusion Gecitabine intratumor administration can inhibite the growth of malignant glioma,attenuate the decrease of weight and extend the life span of the model rats effectively.